Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies.
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: S. Sharma, R. Kurzrock, L. Gouw, D. S. Hong, K. Jones, X. Zhou, H. Shi, H. Fingert, G. S. Falchook
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2589373649